6 unknown. 6 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Unknown 6 |
| Phase 1 | 1 | Unknown 1 |
Follow Frontotemporal Lobar Degeneration: new trials by email Literature Review of Frontotemporal Lobar Degeneration trials Research Report on Frontotemporal Lobar Degeneration
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Influence of [18F]PMPBB3 and [18F]THK5351 PET Distribution Patterns on Post-stroke Cognitive Impairment PMPBB3, THK5351 - Post-stroke Cognitive Impairment, Neuroinflammation | Phase 2 | Unknown | Chang Gung Memorial Hospital | 80 | 2020-11-01 | 2023-05-01 |
| Transcranial Electromagnetic Treatment (TEMT) Against Alzheimer's Disease MemorEM - Alzheimer's Disease | Phase 1 / Phase 2 | Unknown | NeuroEM Therapeutics, Inc. | 6 | 2020-02-10 | 2020-02-17 |
| Alzheimer's Disease: Clinical Investigation and Neuroimage Studies Including 18F-PM-PBB3 and 18F-florbetapir (AV-45) PET Examination F-18 PMPBB3, 18F-florbetapir - Alzheimer's Disease | Phase 2 | Unknown | Chang Gung Memorial Hospital | 70 | 2019-12-01 | 2020-03-12 |
| The Influence of Vascular Burden, Amyloid Plaque and Tau Protein in Patients With Vascular Cognitive Impairment and Dementia With Tauopathy PMPBB3, AV45 - Vascular Cognitive Impairment, Alzheimer's Disease, Fronto-temporal Dementia | Phase 2 | Unknown | Chang Gung Memorial Hospital | 220 | 2018-09-21 | 2023-05-01 |
| Intranasal Oxytocin for Frontotemporal Dementia Syntocinon - Frontotemporal Dementia | Phase 2 | Unknown | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 112 | 2018-01-31 | 2023-12-15 |
| Study to Assess the Safety, Tolerability, and Pharmacodynamic (PD) Effects of FRM-0334 in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation FRM-0334, Placebo - Granulin Mutation | Phase 2 | Unknown | FORUM Pharmaceuticals Inc | 30 | 2014-10-01 | 2016-03-23 |
Frontotemporal Dementia (5) · Alzheimer Disease (3) · Cognitive Dysfunction (1) · Lethargy (1) · Neuroinflammatory Diseases (1) · Pick Disease of the Brain (1) · Plaque, Amyloid (1)
Brain Diseases (6) · Central Nervous System Diseases (6) · Dementia (6) · Mental Disorders (6) · Nervous System Diseases (6) · Neurocognitive Disorders (6) · Neurodegenerative Diseases (6) · Metabolic Diseases (5) · Nutritional and Metabolic Diseases (5) · Proteostasis Deficiencies (5) · TDP-43 Proteinopathies (5) · Pathological Conditions, Signs and Symptoms (3) · Tauopathies (3) · Cognition Disorders (1)
FRM-0334 (1) · Oxytocin (1) · THK5351 (1) · florbetapir (1)
Chang Gung Memorial Hospital (3) · FORUM Pharmaceuticals Inc (1) · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (1) · NeuroEM Therapeutics, Inc. (1)
Taiwan (3) · United States (3) · Belgium (1) · Canada (1) · France (1) · Italy (1) · Netherlands (1) · United Kingdom (1)
PMID 30261917, PMID 34559230, PMID 39862881
2014 (1)